Showing 1511-1520 of 2046 results for "".
- Zeiss to Showcase 3D Visualization and AI Innovations at Euretina 2024https://modernod.com/news/zeiss-to-showcase-3d-visualization-and-ai-innovations-at-euretina-2024/2482438/Zeiss Medical Technology will unveil its latest digital innovations, including advanced 3D visualization technology, as part of the Zeiss Retina Workflow at the upcoming European Society of Retina Specialists (EURETINA) conference, September 19-22, 2024, in Barcelona. Among the inn
- NurExone’s Exosome-Based Exopten Therapy Studied to Treat Glaucomahttps://modernod.com/news/nurexones-exosome-based-exopten-therapy-studied-to-treat-glaucoma/2482339/NurExone Biologic announced a preclinical study to explore the potential of one of the company’s exosome-based therapies, Exopten, in regenerating damaged optic nerves. The study is NurExone Biologic’s latest step in expanding potential clinical indications for its exosome-loaded
- Alcon to Highlight New Data at ASCRS Demonstrating Innovations Designed to Optimize Patient Outcomeshttps://modernod.com/news/alcon-to-highlight-new-data-at-ascrs-demonstrating-innovations-designed-to-optimize-patient-outcomes/2482199/Alcon will showcase approximately 100 company-supported and investigator-led data presentations demonstrating its latest innovative efforts aimed at optimizing patient outcomes at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 5-8, in Boston. In additio
- Zeiss to Showcase New 3D Visualization Technology and Surgical Innovations at ASCRShttps://modernod.com/news/zeiss-to-showcase-new-3d-visualization-technology-and-surgical-innovations-at-ascrs/2482188/Zeiss will showcase the latest in 3D visualization technology and surgical innovation at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 5-8, 2024, in Boston. Building on its Zeiss Medical Ecosystem, several of the new innovations enable seamle
- Survey: Communications Adjustments Could Supercharge Contact Lens Adoptionhttps://modernod.com/news/survey-communications-adjustments-could-supercharge-contact-lens-adoption/2482164/Simple adjustments to how eye care practices communicate with patients may attract a significantly higher number of contact lens wearers, according to new data from the Contact Lens Institute (CLI). The industry association is previewing its latest
- Zeiss’ Visumax 800 With Smile Pro Software Approved by FDAhttps://modernod.com/news/zeiss-visumax-800-with-smile-pro-software-approved-by-fda/2482056/Zeiss Medical Technology announced that the FDA has approved the Visumax 800 With Smile Pro software for surgically treating nearsightedness, with or without astigmatism. This latest generation of femtosecond lasers from Zeiss enters the United States market as the technology is being broadly ado
- Lighthouse Guild to Host Lectures on Ophthalmic Drug Approvals, Technological Innovations, and Advocacy for People with Vision Impairmenthttps://modernod.com/news/lighthouse-guild-to-host-lectures-on-ophthalmic-drug-approvals-technological-innovations-and-advocacy-for-people-with-vision-impairment/2481898/Lighthouse Guild will host three lectures on the latest advances in treatment, technology, and advocacy for people who are blind or have vision loss on Thursday, October 19, 2023, 12-1:30 pm ET, at their headquarters, 250 West 64th Street in Manhattan. Lectures:
- Alcon Showcases New TOTAL30 Multifocal Lenses and Other Innovations at #Academy23https://modernod.com/news/alcon-demonstrates-commitment-to-innovation-at-academy23-showcasing-total30-multifocal/2481884/Alcon will introduce TOTAL30 Multifocal, the first and only reusable Water Gradient multifocal contact lens, along with the latest advancements in eye care technology at the American Academy of Optometry Annual Meeting (#Academy23) in New Orleans, October 11-14, 2023. Alcon&rs
- BVI Completes Enrollment of Finevision HP IDE Clinical Studyhttps://modernod.com/news/bvi-completes-enrollment-of-finevision-hp-ide-clinical-study/2481581/BVI announced it has completed enrollment of its US Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal IOL, Finevision HP. The milestone marks the final implantation of the 539th patient enrolled in the prospective, multicenter, rand
- Notal Vision: Clinical Trials Demonstrate Value of Home OCThttps://modernod.com/news/notal-vision-clinical-trials-demonstrate-value-of-home-oct/2481429/Notal Vision reported that the latest data on its investigational home-based optical coherence tomography (OCT) and how the service can be used to manage wet age-related macular degeneration (AMD) were recently presented at the Angiogenesis, Exudation, and Degeneration and Macula Society 202